





**Premier Manufacturer & Wholesaler of Hemp-derived Cannabinoid Nutraceuticals & Cosmetics**

**Key Stats**



<b>Stock Price</b> 5/3/22	\$1.69
<b>52-Wk Low-high</b>	\$0.54 - \$1.96
<b>Shares Outstanding</b>	13.1M
<b>Market Cap.</b>	\$22.2
<b>Avg. Daily Vol</b> 3-mo.	331
<b>Insider Holdings</b>	88%
<b>Public Float</b>	1.3M
<b>Revenue</b> ttm 12/31/21	\$8.5M
<b>Cash &amp; Equiv.</b> 12/31/21	\$0.3M
<b>Employees</b>	55

**Quarterly Revenue**



**Experienced Management**

- Michael Hill, CEO & Chairman:** 20+ years' executive experience with private & public companies.
- Barrett Evans, President and CSO:** 30+ years' experience in private /public company investment and finance.
- John Bennett, CFO:** 30+ years' senior financial and operation experience for private/public companies.

**Company Contacts**

**Bloomios, Inc.** • HQ Santa Barbara, CA  
bloomios.com • Tel (805) 222-6330

**Investor & Media Relations**

Ron Both & Tim Randall, CMA  
BLMS@cma.team • Tel (949) 432.7566

**Overview**

**About Bloomios**

**Manufacturer** of hemp-derived cannabinoid nutraceutical, cosmetic and pet products.  
**White and private label solutions** for brands, wholesalers and retailers: full product development and compliance.  
**80 turnkey or customizable products** across seven popular format categories.  
**Growth returning** in Q2 2022 following factory expansion and retooling downtime.  
**Pursuing acquisitions** to accelerate growth and capture market share in a target-rich M&A environment.

**Strong R&D & Manufacturing Capability**

**In-house Chemist:** PHD with 15 years' research and hemp industry experience.  
**Quality Management Team:** 10 years' pharmaceutical manufacturing experience.  
**39,000 sf. state-of-the-art manufacturing & warehouse space** in Daytona Beach, FL.

**Recently expanded** automated manufacturing and fulfillment capacity with new, larger scale equipment.  
**Ample capacity for near-term growth plans** with minimal investment.

**Large, Fast-growing Markets**

N. American Cannabinoid market: **33.3% CAGR** to \$61.3 billion by 2027.<sup>1</sup>  
 Global CBD skincare market: **24.8% CAGR** to \$3.9 billion by 2026.<sup>2</sup>

**Recent News Highlights**

- 4/19/22:** 2021 revenue up 545% to \$8.5 million, gross margin expanded from 30.5% to 44.6%. Expecting return to growth in Q2-22 following factory expansion/ retooling.<sup>3</sup>
- 3/31/22:** Selected as exclusive manufacturer for Dryworld's new athletic performance CBD product line.
- 3/16/22:** Engaged CMA to lead new investor and public relations campaign.
- 3/15/22:** Uplisted to OTCQB.

**Expanded Manufacturing Facility**



**Full Range of Customizable Products**


**Consumables**

Gummies: 84 SKUs, Tinctures: 24 SKUs, MSRP \$3.99 - \$250




**Topicals**

37 SKUs, MSRP \$4.99 - \$59.99




**Pet**

22 SKUs, MSRP \$19.99 - \$49.99



**High-Growth Opportunity**

**N. America Cannabinoid Market<sup>1</sup>**



Footnotes: 1) Graphical Research, May 2021; 2) Allied Market Research, Dec. 2021. 3) Outlook issued and effective only as of April 19, 2022. **Important Disclaimer:** This document includes forward looking statements that involves risk and uncertainties as described in the Bloomios, Inc's filings with the U.S. Securities and Exchange Commission and available on sec.gov. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any security. Bloomios makes no guarantee as to the reliability or timeliness of this information; you should not rely on it as the basis for any investment decision. © Bloomios, Inc 2022. All Rights Reserved. Product of CMA. 050622